SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 369.5 Billion KRW | -19.1% |
| 2022 | 456.72 Billion KRW | -50.84% |
| 2021 | 929 Billion KRW | 311.77% |
| 2020 | 225.61 Billion KRW | 22.66% |
| 2019 | 183.93 Billion KRW | 108.61% |
| 2018 | 88.17 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 22.27 Billion KRW | -75.42% |
| 2024 Q2 | 26.77 Billion KRW | 20.24% |
| 2024 Q3 | 61.64 Billion KRW | 130.22% |
| 2023 Q2 | 26.47 Billion KRW | 28.55% |
| 2023 Q1 | 20.59 Billion KRW | -85.32% |
| 2023 Q3 | 231.82 Billion KRW | 775.54% |
| 2023 Q4 | 90.6 Billion KRW | -60.92% |
| 2023 FY | 369.5 Billion KRW | -19.1% |
| 2022 FY | 456.72 Billion KRW | -50.84% |
| 2022 Q4 | 140.3 Billion KRW | 54.09% |
| 2022 Q3 | 91.05 Billion KRW | -34.15% |
| 2022 Q2 | 138.28 Billion KRW | 58.78% |
| 2022 Q1 | 87.09 Billion KRW | -80.68% |
| 2021 Q1 | 112.7 Billion KRW | 68.2% |
| 2021 FY | 929 Billion KRW | 311.77% |
| 2021 Q4 | 450.85 Billion KRW | 104.17% |
| 2021 Q3 | 220.82 Billion KRW | 52.71% |
| 2021 Q2 | 144.6 Billion KRW | 28.3% |
| 2020 FY | 225.61 Billion KRW | 22.66% |
| 2020 Q2 | 39.42 Billion KRW | 73.95% |
| 2020 Q3 | 98.68 Billion KRW | 150.35% |
| 2020 Q4 | 67 Billion KRW | -32.1% |
| 2020 Q1 | 22.66 Billion KRW | -59.24% |
| 2019 FY | 183.93 Billion KRW | 108.61% |
| 2019 Q4 | 55.59 Billion KRW | 10.15% |
| 2019 Q3 | 50.47 Billion KRW | -1.34% |
| 2019 Q2 | 51.15 Billion KRW | 91.53% |
| 2019 Q1 | 26.71 Billion KRW | -33.73% |
| 2018 Q4 | 40.3 Billion KRW | -15.8% |
| 2018 FY | 88.17 Billion KRW | 0.0% |
| 2018 Q3 | 47.86 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ORIENT BIO Inc. | 28 Billion KRW | -1219.421% |
| Green Cross Holdings Corporation | 2057.93 Billion KRW | 82.045% |
| Green Cross Holdings Corporation | 1626.64 Billion KRW | 77.284% |
| Pharmicell Co., Ltd. | 56.22 Billion KRW | -557.163% |
| Green Cross Corporation | 1626.64 Billion KRW | 77.284% |
| GeneOne Life Science, Inc. | 40.2 Billion KRW | -819.101% |
| Celltrion, Inc. | 2176.43 Billion KRW | 83.022% |
| Samsung Biologics Co.,Ltd. | 3694.58 Billion KRW | 89.999% |
| SK Biopharmaceuticals Co., Ltd. | 354.89 Billion KRW | -4.118% |
| Prestige BioPharma Limited | 689.07 Million KRW | -53523.416% |